Try our beta test site

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

This study has been completed.
Information provided by (Responsible Party):
Can-Fite BioPharma Identifier:
First received: September 17, 2008
Last updated: March 31, 2015
Last verified: March 2012
This trial will test the hypothesis that CF102 can safely and effectively suppress viral load in patients with chronic hepatitis C and high circulating levels of virus. The trial will monitor the safety of twice-daily oral dosing with CF102 over a 16-week period; will measure changes in viral load during therapy; and will measure blood concentrations of CF102 at various time points during dosing.

Condition Intervention Phase
Chronic Hepatitis C
Drug: CF 102
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Safety, Tolerability, Biological Activity, and Pharmacokinetics of Orally Administered CF102 in Subjects With Chronic Hepatitis C Genotype 1

Resource links provided by NLM:

Further study details as provided by Can-Fite BioPharma:

Primary Outcome Measures:
  • Adverse Event Profile of Repeated Dosing of CF102 [ Time Frame: 16 weeks ]
  • Effect of Viral Load [ Time Frame: 16 weeks ]
  • Pharmacokinetic Behavior of CF102 During Repeated Dosing [ Time Frame: 16 weeks ]

Secondary Outcome Measures:
  • Evaluation of the Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell Adenosine 3 Receptor (A3R) Expression and Clinical Effects [ Time Frame: 16 weeks ]

Enrollment: 32
Study Start Date: July 2009
Study Completion Date: July 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
CF102 1 mg qd
Drug: CF 102
Oral capsules
Other Name: Cl-IB-MECA
Experimental: 2
CF102 1 mg bid
Drug: CF 102
Oral capsules
Other Name: Cl-IB-MECA
Experimental: 3
CF102 1 mg bid; 16 weeks
Drug: CF 102
Oral capsules
Other Name: Cl-IB-MECA
Placebo Comparator: 5 Drug: Placebo
Matching placebo capsules

Detailed Description:

This is a Phase 1/2, randomized, double-blind, placebo-controlled, dose-escalation study of subjects with chronic hepatitis C genotype 1. Eligible subjects will be assigned in a 3:1 ratio (8 subjects in each cohort) to receive qd or bid treatment for 15 days with oral CF-102 or with placebo. Dose escalation will occur in 2 sequential cohorts.

The decision to continue dosing within a cohort (eg, Subcohort 1a to Subcohort 1b), or to escalate to a new dose level Cohort (eg, Subcohort 1b to Subcohort 2a) will be determined by a blinded independent review of safety data. This review will be conducted by a qualified Safety Review Committee comprising the medical monitor, the consulting toxicologist, and an independent expert clinician.

For the first 2 cohorts, subjects will return to the study center for follow-up assessments on Days 8, 15, and 22. Subjects dosed qd will receive a total of 15 doses of CF-102. Subjects dosed bid will receive a total of 29 doses. The 30th dose has been deleted to accommodate PK sampling on the morning of Day 16, 24 hours after the last dose of CF-102.

For the 3rd cohorts, subjects will return to the study center for follow-up assessments on weeks 2, 4, 8, 12, 16 and 18.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 18 to 60 years of age
  2. Body mass index ≤ 30 kg/m2
  3. Either:

    1. no evidence of cirrhosis, or liver fibrosis corresponding to Metavir Stages 0 to 31 on a liver biopsy performed within the past 2 years, or
    2. a score of F0 or F1 on ActiTest-FibroTest performed within the past year.
  4. Child-Pugh score ≤ 5 at Screening
  5. Serologic evidence of chronic hepatitis C-infection (anti-HCV in serum)
  6. HCV plasma RNA ≥ 1 x 105 IU/mL on 2 separate samples obtained during the screening period.
  7. HCV genotype 1
  8. The following laboratory values must be documented within the Screening period:

    • Hemoglobin > 11.0 g/dL for females and > 12.0 g/dL for males
    • Platelet count > 50 x109/L
    • Normal serum creatinine
    • Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5-fold the upper limit of normal
    • International normalized ratio (INR) ≤ 1.3-fold normal
    • Serum albumin ≥ 3.6 gm/dL
  9. Female subjects cannot be pregnant or breastfeeding and must be either postmenopausal, surgically sterile, abstinent, or using 2 proven methods of birth control
  10. Sexually active male subjects must be practicing acceptable methods of contraception (eg, vasectomy, use of condom plus spermicide, monogamous relationship with a female partner who practices an acceptable method of contraception) during the treatment period
  11. Negative serum ß-human chorionic gonadotropin (HCG, females of child-bearing potential only)
  12. Provide informed consent
  13. Willing to comply with all study requirements

Exclusion Criteria:

  1. Positive test at Screening for human immunodeficiency virus
  2. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug
  3. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the corrected QT (QTc) (Fridericia) interval to > 450 msec for males or > 470 msec for females
  4. Positive results for drugs of abuse at Screening
  5. Donation or loss of more than 400 mL blood within 2 months prior to anticipated dose administration
  6. Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to anticipated dose administration
  7. Previous exposure to CF102(Cohorts 1 and 2 only)
  8. Males whose female partner is pregnant
  9. Serum alpha-feto-protein > 50 ng/mL at screening
  10. Any severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00790673

Rabin Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Can-Fite BioPharma
Study Director: Michael H Silverman, MD Can-Fite BioPharma Ltd
  More Information

Additional Information:
Responsible Party: Can-Fite BioPharma Identifier: NCT00790673     History of Changes
Other Study ID Numbers: CF102-103HCV
Study First Received: September 17, 2008
Results First Received: March 5, 2015
Last Updated: March 31, 2015

Keywords provided by Can-Fite BioPharma:
Hepatitis C
Viral hepatitis

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections processed this record on March 27, 2017